China influenza vaccine market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The government's increased emphasis on and support for the influenza vaccination is one of the major factors influencing the global market. Leading market players like CSL Limited, Sanofi, and GlaxoSmithKline plc are increasing their R&D expenditures in order to enhance their production capabilities and concentrate on the introduction of new vaccines, which is what is causing the industry to continue to grow. GlaxoSmithKline plc (U.K.), Sanofi (France), AstraZeneca (U.K.), CSL Limited (Australia), BIKEN Co., Ltd. (Japan), Abbott (U.S.), Sinovac (China) are the top key players operating in this market.
China Influenza Vaccine Market is valued at around $497.8 Mn in 2022 and is projected to reach $1015.4 Mn by 2030, exhibiting a CAGR of 9.32% during the forecast period 2023-2030.
Each year, flu viruses cause regional epidemics and outbreaks that result in thousands of fatalities. The World Health Organization (WHO) claimed that there were between 3.0-5.0 million severe influenza cases reported in 2022, resulting in 650,000 fatalities globally. The vaccine strain needs to be changed every year to keep up with the evolving global influenza virus strain. The predicted time period will see an increase in product sales as seasonal outbreaks and influenza epidemics occur more frequently.
The World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and other governmental agencies propose a variety of licenced seasonal influenza vaccines to aid in the fight against the illness in the present market environment. Governments are also advocating early immunisation in order to offer the greatest protection possible during flu season. In addition, the pharmaceutical industry continually faces fresh difficulties in creating a vaccine that is effective against a specific strain. Therefore, it is projected that the global market for influenza vaccine would be driven by the increased need for potent flu vaccinations. The government's increased emphasis on and support for the influenza vaccination is one of the major factors influencing the global market. Leading market players like CSL Limited, Sanofi, and GlaxoSmithKline plc are increasing their R&D expenditures in order to enhance their production capabilities and concentrate on the introduction of new vaccines, which is what is causing the industry to continue to grow. GlaxoSmithKline plc (UK), Sanofi (France), AstraZeneca (UK), CSL Limited (Australia), BIKEN Co., Ltd. (Japan), Abbott (US), Sinovac (China) are the top key players operating in this market.
Market Growth Drivers
The rising focus of governments to provide better healthcare for the public, improved vaccine research, and decreased risk of side effects associated with influenza vaccines are a few factors boosting the growth of the global influenza market. The development of innovative vaccines, an increase in medical tourism, and increased financing for R&D activities are all responsible for the market's quick expansion. Additionally, the availability of numerous influenza vaccines that the World Health Organization has prequalified as well as the expansion of immunisation programmes at regular intervals are predicted to benefit the market.
Market Restraints
The primary issues inhibiting the growth of the global influenza market are the length of time required to produce the vaccine and the high production costs linked to very high development.
Key Players
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Manufacturing Technology
By Vaccine Types
By End User
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.